Skip to content

G&A at other companies

EyePoint, Inc.
 logo
EyePoint, Inc. EYPT
$15.24M+9.9%
Ocular Therapeutix logo
Ocular TherapeutixOCUL
$20.01M+22.4%
Kodiak Sciences Inc logo
Kodiak Sciences IncKOD
$11.23M-27.2%
4D Molecular Therapeutics logo
4D Molecular TherapeuticsFDMT
$11.69M-9.7%
Regenxbio logo
RegenxbioRGNX
$21.31M+4.7%
PVL
Palvella TherapeuticsPVLA
$5.52M+45.4%

Other financials

Income statement

See full
Operating income-$11.8M-14.3%
Net income-$10.9M-6.5%
EPS (diluted)-$0.46+81.7%

Balance sheet

See full
Cash & equivalents$34.4M-65.9%
Total debt$1.4M
Total equity$68.6M+7.3%
Total assets$109.8M+6.5%

Cash flow

See full
Operating cash flow-$11.6M-55.6%
CapEx$17.0K
Free cash flow-$7.1M

Valuation

See full
Market cap$96.83M+136%
Enterprise value$63.82M

Returns & leverage

See full
Return on equity-66.6%
Debt / equity
Current ratio12.2×-2.1×

Where this comes from

Reported directly by KLRS in its filing.

Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.

The official record: KLRS’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about KLRS's g&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is KLRS's G&A?
KLRS (KLRS) reported G&A of $4.26M in Q1 2026.
How has KLRS's G&A changed year-over-year?
KLRS's G&A decreased by 1.5% year-over-year, from $4.32M to $4.26M.
What is the long-term trend for KLRS's G&A?
Over 3 years (2021 to 2025), KLRS's G&A has grown at a -32.1% compound annual growth rate (CAGR), from $49.08M to $15.4M.
What does G&A mean?
Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.